Diamyd Medical AB (publ) (ST:DMYD-B) — Market Cap & Net Worth
Market Cap & Net Worth: Diamyd Medical AB (publ) (DMYD-B)
Diamyd Medical AB (publ) (ST:DMYD-B) has a market capitalization of $16.37 Million (Skr152.09 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #25822 globally and #524 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Diamyd Medical AB (publ)'s stock price Skr1.00 by its total outstanding shares 151481380 (151.48 Million). Also see how large is Diamyd Medical AB (publ)'s balance sheet for a full breakdown of the balance sheet.
Diamyd Medical AB (publ) Market Cap History: 2015 to 2026
Diamyd Medical AB (publ)'s market capitalization history from 2015 to 2026. Data shows change from $96.18 Million to $16.37 Million (-17.07% CAGR). Also see Diamyd Medical AB (publ) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Diamyd Medical AB (publ) is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.31 Billion | 0.11% | #123 of 281 |
Weight: Diamyd Medical AB (publ)'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Diamyd Medical AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Diamyd Medical AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Diamyd Medical AB (publ) stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1411.99x
Diamyd Medical AB (publ)'s market cap is 1411.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $106.78 Million | $757.00K | -$32.01 Million | 141.05x | N/A |
| 2017 | $55.10 Million | $922.00K | -$25.55 Million | 59.76x | N/A |
| 2018 | $112.48 Million | $726.00K | -$43.95 Million | 154.93x | N/A |
| 2019 | $405.92 Million | $1.57 Million | -$36.73 Million | 258.87x | N/A |
| 2020 | $502.91 Million | $341.00K | $9.71 Million | 1474.81x | 51.80x |
| 2021 | $241.27 Million | $253.00K | $60.05 Million | 953.62x | 4.02x |
| 2022 | $217.96 Million | $454.00K | -$103.52 Million | 480.08x | N/A |
| 2023 | $107.10 Million | $546.00K | -$116.07 Million | 196.16x | N/A |
| 2024 | $268.00 Million | $130.00K | -$151.85 Million | 2061.55x | N/A |
| 2025 | $183.56 Million | $130.00K | -$169.78 Million | 1411.99x | N/A |
Competitor Companies of DMYD-B by Market Capitalization
Companies near Diamyd Medical AB (publ) in the global market cap rankings as of September 19, 2026. Review DMYD-B goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Diamyd Medical AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Diamyd Medical AB (publ) Historical Marketcap From 2015 to 2026
Between 2015 and today, Diamyd Medical AB (publ)'s market cap moved from $96.18 Million to $ 16.37 Million, with a yearly change of -17.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr16.37 Million | -91.08% |
| 2025 | Skr183.56 Million | -31.51% |
| 2024 | Skr268.00 Million | +150.23% |
| 2023 | Skr107.10 Million | -50.86% |
| 2022 | Skr217.96 Million | -9.66% |
| 2021 | Skr241.27 Million | -52.03% |
| 2020 | Skr502.91 Million | +23.90% |
| 2019 | Skr405.92 Million | +260.87% |
| 2018 | Skr112.48 Million | +104.14% |
| 2017 | Skr55.10 Million | -48.40% |
| 2016 | Skr106.78 Million | +11.02% |
| 2015 | Skr96.18 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Diamyd Medical AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.37 Million USD |
| MoneyControl | $16.37 Million USD |
| MarketWatch | $16.37 Million USD |
| marketcap.company | $16.37 Million USD |
| Reuters | $16.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more